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Sorafenib is a multikinase inhibitor that blocks tumor cell proliferation and angiogenesis. While adverse
skin reactions occur in 90% of patients treated with angiogenesis inhibitors, only a few cases of psor-
iasiform eruption associated with sorafenib therapy have been reported. We report a rare case of
sorafenib-related psoriasis that responded well to topical treatment and narrow-band UV-B photo-
therapy after discontinuation of sorafenib.
Copyright © 2016, Taiwanese Dermatological Association.
Published by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
As the use of targeted therapies has expanded dramatically, the
associated cutaneous side effects have also increased and they
negatively impact patients' quality of life. While various dermato-
logic side effects of sorafenib have been reported, sorafenib-
induced psoriasiform eruption, however, is extremely rare.1e7
Here, we describe a case of psoriasis ﬂare-ups following sorafenib
therapy.Case Report
A 68-year-old Taiwanese male with a history of chronic hepatitis
type B, liver cirrhosis, and hepatocellular carcinoma (HCC) pre-
sented to our dermatology clinic with a complaint of painful skin
eruption on the trunk, buttocks, and lower limbs. He also had a
previous 4-year history of mild, localized plaque-type psoriasis that
had been in remission for at least 40 years. After palliative treat-
ment with transarterial chemoembolization, sorafenib (200 mg
once daily) was initiated for HCC with pulmonary metastasis. Two
months later, numerous sharply demarcated, scaly erythematous
pustular plaques with painful sensation developed on the trunk,
buttocks, and extremities (Figure 1). On admission, the patient wasogy, Taipei Veterans General
u District, Taipei City 11217,
en).
al Association. Published by Elseviafebrile with normal vitals and declared no other simultaneous
medication that was likely to exacerbate the psoriasis.
Skin biopsy revealed focal parakeratosis, Munro microabscesses,
hypogranulosis, neutrophilic spongiform pustules of Kogoj, acan-
thosis, and dilated blood vessels with perivascular inﬁltration of
lymphocytes and neutrophils in the papillary dermis (Figure 2).
Gram and periodic acideSchiff stains in addition to culture taken
from pustules were negative. All these ﬁndings were consistent
with the diagnosis of pustular psoriasis.
After discontinuation of sorafenib, his skin lesions improved
signiﬁcantly under the treatment of a potent topical steroid with
occlusive dressing therapy, topical vitamin D3, and narrow-band
UV-B phototherapy. After discharge, the patient was administered
sorafenib at a substantially lower frequency (200 mg every
2e3 days) by his gastrointestinal doctor. Multiple scaly erythema-
tous papules and plaques reappeared gradually over his trunk,
buttocks, and extremities, but to a lesser extent. There was no
pustule formation as well. The chronological data revealing an
unusual subsequent clinical pattern of lesions when comparedwith
its past history, along with the reappearance of skin lesions after
rechallenge of sorafenib, implied a possible causal relationship
between sorafenib and psoriatic ﬂare-ups.Discussion
Sorafenib as an oral multikinase inhibitor that blocks tumor cell
proliferation and angiogenesis is used for treatment of advanced
renal cell carcinoma, unresectable HCC, and other solid tumors. It
inhibits numerous tyrosine kinases, including the family of vascularer Taiwan LLC. This is an open access article under the CC BY-NC-ND license (http://
Figure 1 Clinical pictures of pustular psoriasis. (A) Extensive guttate erythematous squamous papules coalescing into plaques over the posterior trunk and buttocks. (B) Multiple
large annular, erythematous plaques with overlying silver scale and numerous peripheral micropustules on the posterior thighs.
Figure 2 Histologic appearance of pustular psoriasis. (A) Focal parakeratosis, Munro microabscesses, hypogranulosis, neutrophilic spongiform pustules of Kogoj, acanthosis, and
dilated blood vessels with perivascular inﬁltration of lymphocytes and neutrophils in the papillary dermis. (B) A higher-power view reveals a signiﬁcant subcorneal pustule
[hematoxylin and eosin stain; original magniﬁcations: (A) 40 and (B) 100].
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platelet-derived growth factor receptor, stem cell growth factor
receptor (c-KIT), Fms-like tyrosine-kinase 3, and RET and RAF ki-
nases (RAF-1 and B-RAF).8
About 90% of the patients treated with sorafenib may suffer
from its cutaneous side effects including handefoot skin reaction,
erythematous rash on the face and scalp, subungual splinter
hemorrhages, scalp dysesthesia, alopecia, pruritus, xerosis, spiny
follicular hyperkeratosis, and skin neoplasmas.9 Less commonly
described are areolar hyperkeratosis or pain, eruptive nevi, eruptive
facial cyst, and psoriasiform rash.9
To our knowledge, only seven cases of sorafenib-associated
psoriasiform eruption have been reported, but pathogenesis
remained undetermined.1e7 Dysfunctional CD4þCD25þ immuno-
suppressive regulatory T cells leading to an imbalance between
regulatory and effector T-cell functions may play a crucial role.10 It
has also been suggested that tyrosine kinase inhibitors, such as
sorafenib, may block the signal transduction pathways in both
regulatory and effector T cells.11 However, the occurrence of
psoriasiform eruptions in patients following sorafenib treatment
seems paradoxical, as it blocks the angiogenesis that has been
reported as an overexpression of vascular endothelial growth
factor by keratinocytes in psoriatic lesions.12 In addition, remis-
sion of recalcitrant psoriatic lesions in a patient with metastatic
renal cell carcinoma has been reported after treatment with
sorafenib.13
While cutaneous toxicities associated with sorafenib are usually
manageable and not life-threatening, they may affect critical anti-
neoplastic therapy by causing dose modiﬁcation or discontinuation
of sorafenib. Therefore, early detection and proper management of
these adverse reactions are crucial to continuing treatment with
sorafenib, seeing that skin toxicities in patients treated with sor-
afenib are correlated with a good prognosis in HCC.14The differential diagnosis of pustular psoriasis includes acute
generalized exanthematous pustulosis and subcorneal pustular
dermatosis. Acute generalized exanthematous pustulosis usually
affects a large and ﬂexural area of the body, and is associated with a
limited range of drugs such as antibiotics. In the present case
having the known drug culprit (sorafenib), a diagnosis of sub-
corneal pustular dermatosis is less likely. Although the mechanism
that induces psoriasiform and pustular eruption needs to be clari-
ﬁed, the induction of pustules in our case may be referred to as an
exacerbation of psoriasis accordingly.
Our patient presents a rare case of sorafenib-associated psoriatic
ﬂare-up, which responded dramatically to topical treatment and
narrow-band UV-B phototherapy after discontinuation of sorafenib.
It is of vital importance that dermatologists and other physicians
are conﬁdent in prompt identiﬁcation and management of
sorafenib-induced psoriasiform dermatitis to prevent further
deterioration of patient's quality of life. Further investigations are
also warranted to elucidate the correlation between sorafenib and
psoriasis, and to improve our understanding of this issue so that
more strategies for effective management can be worked out.Acknowledgments
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